Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Jan 13.

Published in final edited form as: Lung Cancer. 2016 Sep 28;101:104–110. doi: 10.1016/j.lungcan.2016.09.015

Figure 3A. Survival and histology. Median overall survival was significantly longer for patients with thymoma compared to other histologies. T: thymoma, TC: thymic carcinoma, TNET: thymic neuroendocrine tumor.

Figure 3B. Survival and mesothelin expression in thymic carcinoma. Median overall survival was significantly longer for patients with >50% expression of mesothelin (not reached) versus ≤50% expression (1.60 years, 95% CI: 1.24–4.94 years), HR 4.46 (95% CI: 1.55–12.80), p=0.0026.

Figure 3A. Survival and histology. Median overall survival was significantly longer for patients with thymoma compared to other histologies. T: thymoma, TC: thymic carcinoma, TNET: thymic neuroendocrine tumor.

Figure 3B. Survival and mesothelin expression in thymic carcinoma. Median overall survival was significantly longer for patients with >50% expression of mesothelin (not reached) versus ≤50% expression (1.60 years, 95% CI: 1.24–4.94 years), HR 4.46 (95% CI: 1.55–12.80), p=0.0026.